Christina Bratcher, MD
Endocrinology, Diabetes & Metabolism · Colorado Springs, CONPI 1255384756
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 62 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 18 manufacturers, the largest accounting for just 16.7% — the pattern of someone who eats at a lot of different presentations.
Across 62 payments — averaging $44.60 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Insulet Corporation$463
- Novo Nordisk$357
- Medtronic$294
- Amgen$229
- Dexcom, Inc.$218
- Sanofi-aventis U.S. LLC$217
- plus $989 from 12 others
Across 24 payments — averaging $900.04 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- AbbVie$22K
What the payments were for
- Food & beverage$2,765100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Insulet Corporation | 13 | $463 |
| Novo Nordisk | 3 | $357 |
| Medtronic(2 entities) | 8 | $294 |
| Amgen | 4 | $229 |
| Dexcom, Inc. | 6 | $218 |
| Sanofi-aventis U.S. LLC | 3 | $217 |
| Tandem Diabetes Care, Inc. | 6 | $210 |
| Lilly USA, LLC | 4 | $146 |
| Mannkind Corporation | 2 | $143 |
| Esperion Therapeutics, Inc. | 1 | $125 |
| Merck | 1 | $81 |
| Abbott | 3 | $63 |
| Nevro Corp. | 1 | $54 |
| Cequr Corporation | 2 | $50 |
| BETA Bionics, Inc. | 1 | $46 |
| Radius Health, Inc. | 2 | $36 |
| BD | 1 | $17 |
| Lifescan, Inc. | 1 | $17 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$2,765 in reported general payments places this provider in the 65th percentile of 120 endocrinology, diabetes & metabolism providers in Colorado.
See all endocrinology, diabetes & metabolism providers in Colorado →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 246 | $380,574 |
| MounjaroTirzepatide | 91 | $149,985 |
| TrulicityDulaglutide | 75 | $120,912 |
| Humalog Kwikpen U-200Insulin Lispro | 46 | $113,435 |
| JardianceEmpagliflozin | 60 | $92,274 |
| Omnipod 5 Dexg7g6 Pods (Gen 5)Insulin Pump Cart,auto,bt,g6/7 | 37 | $65,072 |
| Tresiba Flextouch U-200Insulin Degludec | 35 | $55,179 |
| Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog | 24 | $41,956 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 165 | $34,090 |
| Toujeo SolostarInsulin Glargine,hum.Rec.Anlog | 31 | $32,708 |
| FarxigaDapagliflozin Propanediol | 23 | $29,784 |
| Humalog Kwikpen U-100Insulin Lispro | 60 | $27,613 |
| Fiasp FlextouchInsulin Aspart (Niacinamide) | 24 | $26,929 |
| Tresiba Flextouch U-100Insulin Degludec | 33 | $23,340 |
| JanuviaSitagliptin Phosphate | 12 | $20,554 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic, Novolog | $357 | $387,236268 claims |
| Lilly USA, LLCMounjaro, Trulicity, Humalog, Insulin Lispro | $146 | $282,756216 claims |
| MerckJanuvia, Janumet | $81 | $33,77728 claims |
| Sanofi-aventis U.S. LLCLantus | $217 | $4,37419 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 120 endocrinology, diabetes & metabolism providers in Colorado.
Other endocrinology, diabetes & metabolism in Colorado Springs
- Susan HenleyColorado Springs$9K
- Maria Laarni Subang-DotyColorado Springs$1K
- Leigh PerreaultBoulder$1.7M
- Satish GargAurora$347K
- Viralkumar ShahAurora$256K
- Neda RasouliAurora$188K
- Michelle CassaraArvada$141K
- Halis AkturkAurora$109K
- Irinel StanciuArvada$104K
- Robert EckelAurora$66K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.